Navigation Links
CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
Date:7/28/2011

-family:Arial;font-size:8pt;">$0.13

$0.17Weighted-average common shares outstanding:Basic

27,385

28,24627,385

28,240Diluted

27,745

28,48327,729

28,513Reconciliation excluding items:Income before income taxes, GAAP$3,779$6,314Excluding expenses for business development activities

1,398

2,552Adjusted income before income taxes, non-GAAP5,1778,866Income tax expense calculated at 2011 effective tax rate of 36% for the three and six months

1,864

3,192Adjusted net income, non-GAAP$3,313

$5,674Adjusted income per common share, non-GAAP:Basic$0.12

$0.21Diluted$0.12

$0.20Weighted average common shares outstanding:Basic

27,385

27,385Diluted

27,745

27,729Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP.  In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies.  Non-GAAP adjusted net income and adjusted income per common share exclude expenses for business development activities, including the Company's transaction and integration costs associated with the acquisition of Cardiogenesis.  The Company believes that this non-GAAP presentation provides useful information to investors regarding the operating expense
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
2. CryoLife Makes Equity Investment in ValveXchange® Inc.
3. CryoLife Announces Completion of Acquisition of Cardiogenesis
4. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
5. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
6. CryoLife Posts Record Quarterly Revenues of $30.2 Million
7. CryoLife Launches BioGlue® Surgical Adhesive in Japan
8. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
9. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
10. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
11. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , Engeland, May 23, 2013 ... mannen met lagere urinewegsymptomen geassocieerd met BPH ... Europese dochteronderneming van Astellas Pharma Inc, gebaseerd in ... 4503), kondigde vandaag aan dat het Nederlandse College ter ... VESOMNI in Nederland. De handelsvergunning verleend voor ...
(Date:5/22/2013)... , May 22, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that the Company will present at ... 29, 2013 at the Le Parker Meridian hotel, 119 W. ... . The presentation is scheduled to begin at 2:15 ... About Heska Heska Corporation (NASDAQ: HSKA ...
(Date:5/22/2013)... 2013 Attorney Advertising -- Bronstein, Gewirtz & ... of purchasers of the securities of AMAG Pharmaceuticals, ... The investigation focuses on whether the Company and ... On May 22, 2013, Shares of AMAG dropped ... company announced in regulatory filing that it has ...
Breaking Medicine Technology:Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2
(Date:5/23/2013)... 23 (HealthDay News) -- A shortage of a critical ... across the United States to contain the spread of ... The drug, isoniazid (INH), was first used in 1951 ... the core of any first-line treatment for tuberculosis (TB). ... months, according to the U.S. Centers for Disease Control ...
(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...
(Date:5/23/2013)... 2013 Netsmart today announced it ... of healthcare information technology (HIT) providers for 2013. , The ... of Healthcare Informatics magazine. Netsmart’s ranking of #49 ... strong continued growth is largely due to our commitment to ... of healthcare where resources are scarce, the demand for care ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
Breaking Medicine News(10 mins):Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2
... James S. Forrester, M.D., former chief of the ... the 2009 Lifetime Achievement Award from the American College ... March 29. , Currently the George Burns ... Forrester came to the medical center in 1969 as ...
... These new insights represent an important contribution to future ... prestigious science journal Nature and will be ... molecular mechanisms of hematopoiesis, which will take place in ... findings on the molecular mechanisms of blood formation (hematopoiesis) ...
... Overestimate Amount of Time it Takes to Form a New ... to Achieving Healthier HabitsGREENWICH, Conn., April 1 ... Nestle(R) Pure Life (R) brand bottled water, the number one ... think it takes six months or longer to form a ...
... PALM BEACH GARDENS, Fla., April 1 As ... http://www.silvercensus.com ), a national web ... announced today that it is urging American Veterans ... entitlement from the Veterans Administration called "Aid and ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... April 1 Immunotech Laboratories, Inc. Immunotech Laboratories ... in Puerto Rico with its abstract " Irreversible ... specific novel cytokine stimulation in vitro investigation of ... at the 5th European Conference on Clinical and ...
Cached Medicine News:Health News:ACC presents lifetime achievement award to Cedars-Sinai Heart Institute's James Forrester, M.D. 2Health News:Last step leading to blood cell formation elucidated 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: